3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
38
Kidney Neoplasms
20
Melanoma
14
Neoplasm Metastasis
13
Prostatic Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Lymphoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Vaginal Neoplasms
1
Turcot syndrome
1
Skin Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Interventions
Bevacizumab
5
pembrolizumab
3
Paclitaxel
3
fludarabine
2
Sorafenib
2
Nivolumab
2
Gemcitabine
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
erythromycin propionate-N-acetylcysteinate
1
durvalumab
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
capmatinib
1
belzutifan
1
aflibercept
1
abiraterone
1
Thalidomide
1
Temozolomide
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-2
×
Genitourinary
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled